Baxter Q2 2026: sales up 5.0%, full-year guidance raised
Baxter beat the $0.37 adjusted-EPS consensus by a wide margin with $0.56 and raised full-year guidance, so the quarter is better than the 5.0% sales growth alone suggests. Read the beat carefully: it leans on a one-time $0.11 per-share tariff refund, adjusted EPS still slipped 5.0% from a year ago, and GAAP net income was just $126 million. That combination is why the view below is Neutral rather than Bullish.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS was $0.26 from continuing operations and $0.24 including the discontinued-operations loss, which is why two GAAP figures appear in this filing. Adjusted diluted EPS of $0.56 beat the $0.37 consensus but was down 5.0% from $0.59 a year ago. The company credits a $0.11 per-share IEEPA tariff refund, without which the quarter would look roughly flat.
Sales of $2.96 billion rose 5.0% from $2.81 billion a year earlier, and organic growth was also 5.0%, so currency is not flattering the number. Every segment and division grew, with Advanced Surgery up 12.0% and Medical Products & Therapies up 7.0%. Note that the segment list adds up to more than total sales because the two reporting segments each contain the divisions listed under them.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.